95% CI, 0.75-0.98) among patients without cirrhosis at baseline
Chan, H
Add to that the fact that some people experience diarrhea on tirzepatide , which accelerates fluid loss, and you have a recipe for dehydration headaches
1 A separate two-year extension followed participants with a BMI of 35 or higher who completed the main trial and tolerated their dose
Notably, IF corrects dyslipidemia, reduces WAT accumulation, and decreases inflammation, which reduces CVD and obesity
91 Therefore, clinical studies on conservative treatment are lacking, and, likewise, the natural course is largely unknown